PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

PCSK9 医学 临床试验 入射(几何) 内科学 可欣 疾病 荟萃分析 糖尿病 随机对照试验 肿瘤科 胆固醇 脂蛋白 内分泌学 低密度脂蛋白受体 光学 物理
作者
Amand F. Schmidt,Lucy S Pearce,John T. Wilkins,John P. Overington,Aroon D. Hingorani,Juan P. Casas
出处
期刊:The Cochrane library [Wiley]
卷期号:10: CD011748-CD011748 被引量:211
标识
DOI:10.1002/14651858.cd011748.pub2
摘要

We included 24 studies with data on 60,997 participants. Eighteen trials randomised participants to alirocumab and six to evolocumab. All participants received background lipid-lowering treatment or lifestyle counselling. Six alirocumab studies used an active treatment comparison group (the remaining used placebo), compared to three evolocumab active comparison trials. Alirocumab compared with placebo decreased the risk of CVD events, with an absolute risk difference (RD) of -2% (odds ratio (OR) 0.87, 95% confidence interval (CI) 0.80 to 0.94; 10 studies, 23,868 participants; high-certainty evidence), decreased the risk of mortality (RD -1%; OR 0.83, 95% CI 0.72 to 0.96; 12 studies, 24,797 participants; high-certainty evidence), and MI (RD -2%; OR 0.86, 95% CI 0.79 to 0.94; 9 studies, 23,352 participants; high-certainty evidence) and for any stroke (RD 0%; OR 0.73, 95% CI 0.58 to 0.91; 8 studies, 22,835 participants; high-certainty evidence). Compared to active treatment the alirocumab effects, for CVD, the RD was 1% (OR 1.37, 95% CI 0.65 to 2.87; 3 studies, 1379 participants; low-certainty evidence); for mortality, RD was -1% (OR 0.51, 95% CI 0.18 to 1.40; 5 studies, 1333 participants; low-certainty evidence); for MI, RD was 1% (OR 1.45, 95% CI 0.64 to 3.28, 5 studies, 1734 participants; low-certainty evidence); and for any stroke, RD was less than 1% (OR 0.85, 95% CI 0.13 to 5.61; 5 studies, 1734 participants; low-certainty evidence). Compared to placebo the evolocumab, for CVD, the RD was -2% (OR 0.84, 95% CI 0.78 to 0.91; 3 studies, 29,432 participants; high-certainty evidence); for mortality, RD was less than 1% (OR 1.04, 95% CI 0.91 to 1.19; 3 studies, 29,432 participants; high-certainty evidence); for MI, RD was -1% (OR 0.72, 95% CI 0.64 to 0.82; 3 studies, 29,432 participants; high-certainty evidence); and for any stroke RD was less than -1% (OR 0.79, 95% CI 0.65 to 0.94; 2 studies, 28,531 participants; high-certainty evidence). Compared to active treatment, the evolocumab effects, for any CVD event RD was less than -1% (OR 0.66, 95% CI 0.14 to 3.04; 1 study, 218 participants; very low-certainty evidence); for all-cause mortality, the RD was less than 1% (OR 0.43, 95% CI 0.14 to 1.30; 3 studies, 5223 participants; very low-certainty evidence); and for MI, RD was less than 1% (OR 0.66, 95% CI 0.23 to 1.85; 3 studies, 5003 participants; very low-certainty evidence). There were insufficient data on any stroke. AUTHORS' CONCLUSIONS: The evidence for the clinical endpoint effects of evolocumab and alirocumab were graded as high. There is a strong evidence base to prescribe PCSK9 monoclonal antibodies to people who might not be eligible for other lipid-lowering drugs, or to people who cannot meet their lipid goals on more traditional therapies, which was the main patient population of the available trials. The evidence base of PCSK9 inhibitors compared with active treatment is much weaker (low very- to low-certainty evidence) and it is unclear whether evolocumab or alirocumab might be effectively used as replacement therapies. Related, most of the available studies preferentially enrolled people with either established CVD or at a high risk already, and evidence in low- to medium-risk settings is minimal. Finally, there is very limited evidence on any potential safety issues of both evolocumab and alirocumab. While the current evidence synthesis does not reveal any adverse signals, neither does it provide evidence against such signals. This suggests careful consideration of alternative lipid lowering treatments before prescribing PCSK9 inhibitors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
天天向上的应助被学术雷锋采纳,获得50
1秒前
1秒前
1秒前
gaoyi12356发布了新的文献求助10
1秒前
清脆靳完成签到,获得积分10
2秒前
千帆完成签到,获得积分10
2秒前
111完成签到,获得积分10
3秒前
曾经的贞完成签到,获得积分10
4秒前
秋风的应助被无辜访彤采纳,获得10
4秒前
4秒前
4秒前
风汐5423完成签到,获得积分10
5秒前
5秒前
5秒前
tudou发布了新的文献求助20
5秒前
歪歪完成签到,获得积分10
6秒前
猪猪猪完成签到,获得积分20
6秒前
再等等就回家完成签到,获得积分20
7秒前
7秒前
ian发布了新的文献求助10
7秒前
xuexue完成签到,获得积分10
7秒前
ying发布了新的文献求助10
7秒前
天天学习完成签到,获得积分20
8秒前
cc完成签到,获得积分0
8秒前
丰丰发布了新的文献求助10
8秒前
9秒前
Raza完成签到,获得积分10
9秒前
zheng完成签到 ,获得积分10
9秒前
syvshc的应助被缓慢半山采纳,获得10
10秒前
acer08完成签到,获得积分10
10秒前
10秒前
风趣紫发布了新的文献求助10
10秒前
10秒前
黄毛虎发布了新的文献求助10
10秒前
天天快乐的应助被AZ采纳,获得10
11秒前
ddddduan发布了新的文献求助10
11秒前
ubless607发布了新的文献求助10
12秒前
阳光热狗完成签到,获得积分10
12秒前
佛手柑完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187480
求助须知:如何正确求助?哪些是违规求助? 9575554
关于积分的说明 21841909
捐赠科研通 7785230
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559412
邀请新用户注册赠送积分活动 2481898